E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Marine Microalgae"

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: 31 January 2018

Special Issue Editors

Guest Editor
Dr. Adele Cutignano

Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, via Campi Flegrei 34, 80078 Pozzuoli, Napoli, Italy
Website | E-Mail
Interests: marine natural products; structural elucidation; biosynthesis; bioactive molecules; drug discovery; lipidomics
Guest Editor
Dr. Giovanna Romano

Stazione Zoologica Anton Dohrn, Villa Comunale 1, 80121, Napoli, Italy
Website | E-Mail
Interests: chemical ecology; microalgae; bioactive molecules; marine natural products

Special Issue Information

Dear Colleagues,

Marine microalgae are the most diverse group of photosynthetic organisms living in the oceans. They have proved to be a surprising wealth of high value substances with potential as pharmaceuticals, nutritional supplements, and cosmeceuticals. In addition, due to the high content of lipids, they have gained interest as an exploitable and sustainable source of biofuels. Despite this, we still have poor knowledge regarding their metabolic pathways, often compared to plants, but, according to recent biochemical and molecular evidence, they are truly different. The striking plasticity by which they tune the levels of the end products of their metabolism suggests finely regulated metabolic fluxes in sensibly complex and peculiar biochemical networks.

This Special Issue welcomes contributions from all fields of biosynthesis, metabolism and bioactive natural products and lipids from marine microalgae, aiming at a deeper comprehension and development of chemical and biochemical features of this fascinating group of microorganisms.

Dr. Adele Cutignano
Dr. Giovanna Romano
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Bioactive molecules
  • Drug discovery
  • Structural characterization
  • Biosynthesis
  • Biochemical pathways
  • Lipidomics
  • Lipid metabolism
  • Chemical ecology
  • Secondary metabolites

Published Papers (2 papers)

View options order results:
result details:
Displaying articles 1-2
Export citation of selected articles as:

Research

Open AccessArticle Development of a Dunaliella tertiolecta Strain with Increased Zeaxanthin Content Using Random Mutagenesis
Mar. Drugs 2017, 15(6), 189; doi:10.3390/md15060189
Received: 20 February 2017 / Revised: 12 June 2017 / Accepted: 18 June 2017 / Published: 21 June 2017
PDF Full-text (2735 KB) | HTML Full-text | XML Full-text | Supplementary Files
Abstract
Zeaxanthin is a xanthophyll pigment that is regarded as one of the best carotenoids for the prevention and treatment of degenerative diseases. In the worldwide natural products market, consumers prefer pigments that have been produced from biological sources. In this study, a Dunaliella
[...] Read more.
Zeaxanthin is a xanthophyll pigment that is regarded as one of the best carotenoids for the prevention and treatment of degenerative diseases. In the worldwide natural products market, consumers prefer pigments that have been produced from biological sources. In this study, a Dunaliella tertiolecta strain that has 10–15% higher cellular zeaxanthin content than the parent strain (zea1), was obtained by random mutagenesis using ethyl methanesulfonate (EMS) as a mutagen. This mutant, mp3, was grown under various salinities and light intensities to optimize culture conditions for zeaxanthin production. The highest cellular zeaxanthin content was observed at 1.5 M NaCl and 65–85 μmol photons·m−2·s−1, and the highest daily zeaxanthin productivity was observed at 0.6 M NaCl and 140–160 μmol photons·m−2·s−1. The maximal yield of zeaxanthin from mp3 in fed-batch culture was 8 mg·L−1, which was obtained at 0.6 M NaCl and 140–160 μmol photons·m−2·s−1. These results suggest that random mutagenesis with EMS is useful for generating D. tertiolecta strains with increased zeaxanthin content, and also suggest optimal culture conditions for the enhancement of biomass and zeaxanthin production by the zeaxanthin accumulating mutant strains. Full article
(This article belongs to the Special Issue Marine Microalgae)
Figures

Figure 1

Open AccessArticle The Missing Piece in Biosynthesis of Amphidinols: First Evidence of Glycolate as a Starter Unit in New Polyketides from Amphidinium carterae
Mar. Drugs 2017, 15(6), 157; doi:10.3390/md15060157
Received: 28 April 2017 / Revised: 22 May 2017 / Accepted: 25 May 2017 / Published: 31 May 2017
PDF Full-text (1870 KB) | HTML Full-text | XML Full-text | Supplementary Files
Abstract
Two new members of the amphidinol family, amphidinol A (1) and its 7-sulfate derivative amphidinol B (2), were isolated from a strain of Amphidinium carterae of Lake Fusaro, near Naples (Italy), and chemically identified by spectroscopic and spectrometric methods.
[...] Read more.
Two new members of the amphidinol family, amphidinol A (1) and its 7-sulfate derivative amphidinol B (2), were isolated from a strain of Amphidinium carterae of Lake Fusaro, near Naples (Italy), and chemically identified by spectroscopic and spectrometric methods. Amphidinol A showed antifungal activity against Candida albicans (MIC = 19 µg/mL). Biosynthetic experiments with stable isotope-labelled acetate allowed defining the elongation process in 1. For the first time the use of glycolate as a starter unit in the polyketide biosynthesis of amphidinol metabolites was unambiguously demonstrated. Full article
(This article belongs to the Special Issue Marine Microalgae)
Figures

Journal Contact

MDPI AG
Marine Drugs Editorial Office
St. Alban-Anlage 66, 4052 Basel, Switzerland
E-Mail: 
Tel. +41 61 683 77 34
Fax: +41 61 302 89 18
Editorial Board
Contact Details Submit to Special Issue Edit a special issue Review for Marine Drugs
logo
loading...
Back to Top